962 related articles for article (PubMed ID: 14707283)
1. The MDM2-p53 interaction.
Moll UM; Petrenko O
Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
[TBL] [Abstract][Full Text] [Related]
2. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
Brignone C; Bradley KE; Kisselev AF; Grossman SR
Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
[TBL] [Abstract][Full Text] [Related]
3. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
[TBL] [Abstract][Full Text] [Related]
4. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
5. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
[TBL] [Abstract][Full Text] [Related]
6. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin ligase COP1 is a critical negative regulator of p53.
Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
[TBL] [Abstract][Full Text] [Related]
8. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
9. Hypophosphorylation of Mdm2 augments p53 stability.
Blattner C; Hay T; Meek DW; Lane DP
Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
[TBL] [Abstract][Full Text] [Related]
10. Regulation of p53 by Mdm2: fate is in the numbers.
Shmueli A; Oren M
Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
[TBL] [Abstract][Full Text] [Related]
11. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
[TBL] [Abstract][Full Text] [Related]
12. Regulation of p53 and MDM2 activity by MTBP.
Brady M; Vlatkovic N; Boyd MT
Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
[TBL] [Abstract][Full Text] [Related]
13. MDM2 promotes ubiquitination and degradation of MDMX.
Pan Y; Chen J
Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
[TBL] [Abstract][Full Text] [Related]
14. Regulation of p53 stability by Mdm2.
Kubbutat MH; Jones SN; Vousden KH
Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
Jin Y; Lee H; Zeng SX; Dai MS; Lu H
EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
[TBL] [Abstract][Full Text] [Related]
16. The p53-Mdm2 module and the ubiquitin system.
Michael D; Oren M
Semin Cancer Biol; 2003 Feb; 13(1):49-58. PubMed ID: 12507556
[TBL] [Abstract][Full Text] [Related]
17. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
[TBL] [Abstract][Full Text] [Related]
18. Monoubiquitination: the signal for p53 nuclear export?
Brooks CL; Li M; Gu W
Cell Cycle; 2004 Apr; 3(4):436-8. PubMed ID: 14976431
[TBL] [Abstract][Full Text] [Related]
19. Activation and activities of the p53 tumour suppressor protein.
Bálint E E; Vousden KH
Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
[TBL] [Abstract][Full Text] [Related]
20. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells.
Kashuba E; Mattsson K; Pokrovskaja K; Kiss C; Protopopova M; Ehlin-Henriksson B; Klein G; Szekely L
Int J Cancer; 2003 Jul; 105(5):644-53. PubMed ID: 12740913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
